Skip to main content
. Author manuscript; available in PMC: 2023 Dec 29.
Published in final edited form as: Br J Haematol. 2023 May 22;202(3):686–689. doi: 10.1111/bjh.18881

Figure 2: Correlation between CD8 or FOXP3 immunostaining and survival at 10 years follow-up.

Figure 2:

Progression free survival (months) at 10 years follow-up in the subgroups of patients in the subgroups of patients with high (A) and low CD8 counts (B). Patients with high amounts of CD8+ T-cells (>7%) display a significant benefit of the R-maintenance regimen (A), whereas this benefit shows a just trend in patients with low amounts of CD8+ T-cells (B). Patients with low amounts of FOXP3+ Tregs (≤4%) display a significant benefit of the R-maintenance regimen (C), whereas this benefit shows a just trend in pts with high amounts of FOXP3+ Tregs (D).